These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37783568)

  • 1. Emerging Process Modeling Capabilities for Dry Powder Operations for Inhaled Formulations.
    Lou H; Ding L; Wu T; Li W; Khalaf R; Smyth HDC; Reid DL
    Mol Pharm; 2023 Nov; 20(11):5332-5344. PubMed ID: 37783568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focusing on powder processing in dry powder inhalation product development, manufacturing and performance.
    Stegemann S; Faulhammer E; Pinto JT; Paudel A
    Int J Pharm; 2022 Feb; 614():121445. PubMed ID: 34998921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW; Schneider M; Morrical BD; Imanidis G
    J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of capsule dosing techniques for use in dry powder inhalers.
    Edwards D
    Ther Deliv; 2010 Jul; 1(1):195-201. PubMed ID: 22816126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers.
    Sommerfeld M; Cui Y; Schmalfuß S
    Eur J Pharm Sci; 2019 Feb; 128():299-324. PubMed ID: 30553814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in lactose blend formulations for carrier-based dry powder inhalation.
    Hebbink GA; Jaspers M; Peters HJW; Dickhoff BHJ
    Adv Drug Deliv Rev; 2022 Oct; 189():114527. PubMed ID: 36070848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent developments in the computational simulation of dry powder inhalers.
    Capecelatro J; Longest W; Boerman C; Sulaiman M; Sundaresan S
    Adv Drug Deliv Rev; 2022 Sep; 188():114461. PubMed ID: 35868587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carrier-based dry powder inhalation: Impact of carrier modification on capsule filling processability and in vitro aerodynamic performance.
    Faulhammer E; Wahl V; Zellnitz S; Khinast JG; Paudel A
    Int J Pharm; 2015 Aug; 491(1-2):231-42. PubMed ID: 26136200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating inter-patient variability of dispersion in dry powder inhalers using CFD-DEM simulations.
    Benque B; Khinast JG
    Eur J Pharm Sci; 2021 Jan; 156():105574. PubMed ID: 32980431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of drug alone and carrier-based GLP-1 dry powder inhaler formulations.
    Babenko M; Alany RG; Calabrese G; Kaialy W; ElShaer A
    Int J Pharm; 2022 Apr; 617():121601. PubMed ID: 35181460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of Low Air Volume Dry Powder Inhalers (LV-DPI) when Aerosolizing Excipient Enhanced Growth (EEG) Surfactant Powder Formulations.
    Boc S; Momin MAM; Farkas DR; Longest W; Hindle M
    AAPS PharmSciTech; 2021 Apr; 22(4):135. PubMed ID: 33860378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CFD-DEM investigation of the effects of aperture size for a capsule-based dry powder inhaler.
    Zhu Q; Kakhi M; Jayasundara C; Walenga R; Behara SRB; Chan HK; Yang R
    Int J Pharm; 2023 Nov; 647():123556. PubMed ID: 37890648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Particle-based coarse-grained approach for simulating dry powder inhaler.
    Liu X; Sulaiman M; Kolehmainen J; Ozel A; Sundaresan S
    Int J Pharm; 2021 Sep; 606():120821. PubMed ID: 34171427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low powder mass filling of dry powder inhalation formulations.
    Eskandar F; Lejeune M; Edge S
    Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of material attributes and process parameters on the powder bed uniformity during a low-dose dosator capsule filling process.
    Stranzinger S; Faulhammer E; Calzolari V; Biserni S; Dreu R; Šibanc R; Paudel A; Khinast JG
    Int J Pharm; 2017 Jan; 516(1-2):9-20. PubMed ID: 27826028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possibilities and advantages of additive manufacturing in dry powder formulations for inhalation.
    Wostry M; Scherließ R
    Eur J Pharm Sci; 2023 Nov; 190():106583. PubMed ID: 37703932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of dispersion enhancer selection in the development of novel tratinterol hydrochloride dry powder inhalation formulations.
    Liu T; Tong S; Liao Q; Pan L; Cheng M; Rantanen J; Cun D; Yang M
    Int J Pharm; 2023 Mar; 635():122702. PubMed ID: 36773729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixing of dry powders for inhalation: A review.
    Spahn JE; Zhang F; Smyth HDC
    Int J Pharm; 2022 May; 619():121736. PubMed ID: 35405281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deposition and fine particle production during dynamic flow in a dry powder inhaler: a CFD approach.
    Milenkovic J; Alexopoulos AH; Kiparissides C
    Int J Pharm; 2014 Jan; 461(1-2):129-36. PubMed ID: 24296048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.